Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27548955 | 0.80 | CHRNB2 (0.44) | ALDH1A1 | |
| SCHEMBL2586974 | 0.79 | MAPT (0.46) | MAPTALDH1A1 | |
| SCHEMBL20827233 | 0.78 | MAPT (0.37) | MAPTALDH1A1NPC1 | |
| SCHEMBL6539422 | 0.76 | MAPT (0.40) | MAPTALDH1A1NPC1 | |
| SCHEMBL6539433 | 0.76 | MAPT (0.40) | MAPTALDH1A1NPC1 | |
| SCHEMBL12725522 | 0.71 | KDM4E (0.39) | MAPTALDH1A1 | |
| SCHEMBL15800725 | 0.71 | KDM4E (0.39) | MAPTALDH1A1 | |
| SCHEMBL472121 | 0.71 | MAPT (0.44) | MAPTALDH1A1 | |
| SCHEMBL11816487 | 0.71 | ALDH1A1 (0.41) | MAPTALDH1A1 | |
| SCHEMBL9430085 | 0.71 | ALDH1A1 (0.37) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113444102-A | Fused tetracyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-111433206-A | Compound (I) | 葛兰素史克知识产权开发有限公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-102471310-A | Bipyridines useful for the treatment of proliferative diseases | NOVARTIS AG | 2012-05-23 | — | — | CN | disclosed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| EP-1537106-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | MAPT 96/4885ALDH1A1 944/4885NPC1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.